Features | Partner Sites | Information | LinkXpress
Sign In
GLOBETECH PUBLISHING LLC
GLOBETECH MEDIA
GLOBETECH PUBLISHING LLC

Partnership to Promote Multiple-Use Filters and Connectors for the Biopharmaceutical Industry

By BiotechDaily International staff writers
Posted on 30 Sep 2013
Image: The Intact Modular Filler (IMF) is a fully integrated, automatic filling machine performing all filling activities, including container loading, positioning, filling, and container unloading. The IMF can fill glass or plastic containers of various shapes and sizes (bottles, vials, pouches) with high precision and consistency (Photo courtesy of Medical Instill Technologies).
Image: The Intact Modular Filler (IMF) is a fully integrated, automatic filling machine performing all filling activities, including container loading, positioning, filling, and container unloading. The IMF can fill glass or plastic containers of various shapes and sizes (bottles, vials, pouches) with high precision and consistency (Photo courtesy of Medical Instill Technologies).
A partnership has been established to promote the utilization of multiple-use sterile filtration and connection devices in the biopharmaceutical industry.

ATMI, Inc. (Danbury, CT, USA), a global technology company and leader in single-use bioprocess solutions, announced that it will be investing in the INTACT family of sterile connector and sterile fill technologies developed by Medical Instill Technologies (New Milford, CT, USA), a company dedicated to developing solutions for the transfer and packaging of high purity fluids. Medinstill says that INTACT connector is the only multiple-use sterile connector now available that guarantees no contact between the liquid path and the external environment ensuring no ingress of air, bacteria, yeasts, or molds.

The Intact Modular Filler (IMF) is a fully integrated, automatic filling machine performing all filling activities, including container loading, positioning, filling, and container unloading. The IMF can fill glass or plastic containers of various shapes and sizes (bottles, vials, pouches) with high precision and consistency.

ATMI and Medinstill will market and manufacture INTACT technology solutions for the biopharmaceutical industry. This technology is scalable from small lots in benchtop systems to industrial-sized units for manufacturers in the global biopharmaceutical and vaccine markets.

“ATMI has a strong history of internal innovation as well as collaboration with other innovators,” said, Doug Neugold CEO of ATMI. “Collaboration with Medinstill is another great example of this strategy. Through this investment, we will develop a suite of products that address critical issues from our customers’ perspective as they continue to adopt single-use technology and other new inventions. Our customers are looking for ways to reduce cost, minimize time to market and increase manufacturing flexibility. The INTACT solutions that we are developing with Medinstill enable efficiencies that will help us help them realize their objectives.”

“We are happy to partner with a company of ATMI’s stature,” said Dr. Daniel Py, chairman of Medinstill. “With its global reach and history of technical innovation in biopharmaceutical manufacturing, I believe ATMI can be instrumental in allowing us to bring products with the highest safety levels to those in need. The INTACT technology provides a means to rapidly reduce drug shortages while overcoming the difficulties associated with installing and running aseptic lines in emerging markets, such as access to specially trained personnel, all at a fraction of the cost of traditional aseptic filling lines. The synergy between our INTACT Closed Transfer Systems and disposable technologies from ATMI allows us together to quickly install turnkey fill finish lines, bringing many benefits to a large number of manufacturers. We look forward to a long and successful relationship with ATMI.”

Related Links:
ATMI, Inc.
Medical Instill Technologies



Channels

Genomics/Proteomics

view channel
Image: Bacteriophage EFDG1 visualized by transmission electron microscopy (TEM) at a magnification of 20,000–30,000 times. Note that some phages are still bound to remains of the dead bacteria (Photo courtesy of the Hebrew University of Jerusalem).

Bacteriophage Therapy Eliminates Multidrug Resistant Bacterial Infections

Bacteriophage therapy has been shown to be an effective approach for treating infections caused by drug-resistant strains of the bacterium Enterococcus faecalis. E. faecalis, a bacterium inhabiting... Read more

Drug Discovery

view channel
Image: Molecular model of the protein Saposin C (Photo courtesy of Wikimedia Commons).

Nanovesicles Kill Human Lung Cancer Cells in Culture and in a Mouse Xenograft Model

Nanovesicles assembled from the protein Saposin C (SapC) and the phospholipid dioleoylphosphatidylserine (DOPS) were shown to be potent inhibitors of lung cancer cells in culture and in a mouse xenograft model.... Read more

Biochemistry

view channel

Possible New Target Found for Treating Brain Inflammation

Scientists have identified an enzyme that produces a class of inflammatory lipid molecules in the brain. Abnormally high levels of these molecules appear to cause a rare inherited eurodegenerative disorder, and that disorder now may be treatable if researchers can develop suitable drug candidates that suppress this enzyme.... Read more

Lab Technologies

view channel
Image: The FLUOVIEW FVMPE-RS Gantry microscope (Photo courtesy of Olympus).

New Multiphoton Laser Scanning Microscope Configurations Expand Research Potential

Two new configurations of a state-of-the-art multiphoton laser scanning microscope extend the usefulness of the instrument for examining rapidly occurring biological events and for obtaining images from... Read more
 
Copyright © 2000-2015 Globetech Media. All rights reserved.